Lv5
1338 积分 2024-04-18 加入
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
6小时前
待确认
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
1天前
已完结
Association between HER-2 and lymph node metastasis in gastric cancer: a meta-analysis
1个月前
已关闭
Overcoming therapy resistance in EGFR-mutant lung cancer
1个月前
已完结
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
1个月前
已完结
MA12.06 PAPILLON: TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC
2个月前
已关闭
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications
2个月前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
2个月前
已完结
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
2个月前
已完结
皖公网安备34019202002308
